Target
Gimeracil
4 abstracts
Abstract
A phase 3, randomized study of adjuvant rilvegostomig plus chemotherapy in resected biliary tract cancer: ARTEMIDE-Biliary01.Org: Mayo Clinic Comprehensive Cancer Center, IRCCS San Raffaele Hospital, UCL Cancer Institute, Cedars-Sinai Medical Center, Memorial Sloan Kettering Cancer Center,
Abstract
ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) cancer.Org: Shizuoka Cancer Center, National Cancer Center Hospital East, Kashiwa, Japan, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Beijing Cancer Hospital, Department of Oncology, National Taiwan University Hospital,
Abstract
The impact of neighborhood socioeconomic deprivation on clinical trial enrollment at an NCI-designated cancer center.Org: University of Kentucky, Lexington, KY, Markey Cancer Center, University of Kentucky, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, H. Lee Moffitt Cancer Center and Research Institute, University of Kentucky, College of Medicine,
Abstract
Real-world efficacy of chemotherapy in patients with advanced extramammary Paget's disease: A retrospective, multicenter study of 204 Japanese patients.Org: Kumamoto University Hospital, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan, Nagoya City University Graduate School of Medical Sciences, National Cancer Center Hospital East, Kashiwa, Japan, Graduate School of Medicine, Chiba University,